Strides Pharma Science Ltd. has announced that its step-down, wholly-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Lidocaine Ointment USP 5% from the USFDA. This is a generic version of Xylocaine Ointment of AstraZeneca Pharmaceuticals LP.
According to IQVIA MAT data, the US market for Lidocaine Ointment USP 5% is approximately $50-mn. The product will be marketed by Strides Pharma Inc. in the US market and will be launched immediately.
Strides Pharma Inc has 80 cumulative ANDA filings with USFDA of which 54 ANDAs have been approved as of date and 26 are pending approval.
Strides Vivimed JV receives approval for albendazole tablets
In another development, Strides has announced that its 50:50 JV Strides Vivimed Pte. Ltd., Singapore has received approval for Albendazole Tablets USP 200 mg from the US FDA. This is the second generic approval by the USFDA for Albendazole Tablets.
The drug to be launched by Strides is a generic version of Albenza Tablets of Amneal Pharmaceuticals, Inc., and had annual sales of approximately $100-mn.
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
High Value Painting Exhibition "Explosive" Furniture Painting Inspiration Muse
Introduction to Toluene: Morning Analysis of Toluene Market on March 19
Introduction to Styrene: Morning Analysis of Styrene Market on March 19
Convergence and Breakthrough of Wanyi Pilan Distributor Association
Technology is the first productivity Delia added new honor
Introduction to Pure Benzene